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Aims To assess the prognostic significance of infarct core tissue characteristics using cardiac magnetic resonance (CMR)
imaging in survivors of acute ST-elevation myocardial infarction (STEMI).
Methods
and results
We performed an observational prospective single centre cohort study in 300 reperfused STEMI patients (mean+
SD age 59+ 12 years, 74% male) who underwent CMR 2 days and 6 months post-myocardial infarction (n ¼ 267).
Native T1 was measured in myocardial regions of interest (n ¼ 288). Adverse remodelling was defined as an increase
in left ventricular (LV) end-diastolic volume ≥20% at 6 months. All-cause death or first heart failure hospitalization
was a pre-specified outcome that was assessed during follow-up (median duration 845 days). One hundred and sixty
(56%) patients had a hypo-intense infarct core disclosed by native T1. In multivariable regression, infarct core native
T1 was inversely associated with adverse remodelling [odds ratio (95% confidence interval (CI)] per 10 ms reduction
in native T1: 0.91 (0.82, 0.00); P ¼ 0.061). Thirty (10.4%) of 288 patients died or experienced a heart failure event and
13 of these events occurred post-discharge. Native T1 values (ms) within the hypo-intense infarct core (n ¼ 160
STEMI patients) were inversely associated with the risk of all-cause death or first hospitalization for heart failure
post-discharge (for a 10 ms increase in native T1: hazard ratio 0.730, 95% CI 0.617, 0.863; P, 0.001) including after
adjustment for left ventricular ejection fraction, infarct core T2 and myocardial haemorrhage. The prognostic results
for microvascular obstruction were similar.
Conclusion Infarct core native T1 represents a novel non-contrast CMR biomarker with potential for infarct characterization and
prognostication in STEMI survivors. Confirmatory studies are warranted.
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Clinical perspective
Contrast-enhanced cardiac magnetic resonance (CMR) imaging is the established approach for imaging infarct pathology in survivors of
ST-elevation myocardial infarction (STEMI). The pathophysiological and prognostic importance of infarct pathology disclosed by non-
contrast native T1 CMR mapping in acute STEMI patients is unknown. We performed a prospective single centre cohort study in 300 re-
perfused STEMI patients who underwent CMR 2 days and 6 months (n ¼ 267) post-myocardial infarction and clinical follow-up (median
duration 2.5 years). Infarct core pathology revealed by native T1 mapping was feasible [n ¼ 288 (96%) with evaluable data] and had superior
prognostic value compared with infarct core T2 and myocardial haemorrhage, and similar prognostic value compared with microvascular
obstruction revealed by late gadolinium enhancement CMR. Infarct core native T1 is a novel non-contrast CMR biomarker with potential
for infarct characterization and prognostication in STEMI survivors.
Introduction
Myocardial infarct size1,2 and microvascular obstruction3–5 revealed
by contrast-enhanced cardiac magnetic resonance (CMR) reflect
the efficacy of reperfusion therapy and are prognostically important
findings in survivors of ST-elevation myocardial infarction (STEMI).
Human tissue has fundamental magnetic properties, including the
longitudinal (spin-lattice) relaxation time (native T1 in milliseconds).
Native T1 is influenced by water content, binding with macromole-
cules (water mobility), and cell content.6,7 Native T1 CMR does not
involve an intravenous contrast agent. Tissue water content in-
creases as a result of ischaemia and longer T1 times may represent
a biomarker of localized myocardial injury.8–16
The clinical significance of tissue changes within the infarct core in
patients with acute reperfused STEMI has not been directly as-
sessed. We hypothesized that baseline native T1 values would be
(i) inversely associated with the severity of MI, including microvascu-
lar obstruction, (ii) independently associated with left ventricular
(LV) remodelling, and (iii) independently associated with pre-
defined health outcomes. Should these hypotheses be confirmed
then infarct core native T1 mapping without an intravenous contrast
agent might have potential as an alternative biomarker to micro-
vascular obstruction revealed by contrast-enhanced CMR.
To investigate these hypotheses, we measured native T1 in myo-
cardial regions of interest in STEMI patients undergoing serial CMR
imaging 2 days and 6 months post-MI. We assessed the clinical as-
sociates of native T1 within the hypo-intense infarct core and sub-
sequent LV remodelling and examined its association with all-cause
death and first hospitalization for heart failure.
Methods
Study population and ST-elevation
myocardial infarction management
We performed an observational prospective CMR cohort study in a sin-
gle regional cardiac centre between 14 July 2011 and 22 November
2012. Three hundred and forty three STEMI patients provided written
informed consent to undergo CMR 2 days and 6 months post-MI. Pa-
tients were eligible if they had an indication for primary percutaneous
coronary intervention (PCI) or thrombolysis for acute STEMI due to a
history of symptoms consistent with acute myocardial ischaemia
and with supporting changes on the electrocardiogram (ECG) (i.e.
ST-segment elevation or new left bundle-branch block).17 Exclusion
criteria represented standard contra-indications to contrast CMR,
including a pacemaker and estimated glomerular filtration rate
,30 mL/min/1.73 m2. The study was approved by the National
Research Ethics Service and all participants provided written informed
consent. Acute STEMI management followed contemporary guide-
lines.17,18 Aspiration thrombectomy, direct stenting, anti-thrombotic
drugs, and other therapies were administered according to clinical judg-
ment (Supplementary material online, Methods). The ClinicalTrials.gov
identifier is NCT02072850.
Cardiac magnetic resonance acquisition
Cardiac magnetic resonance was performed on a Siemens MAGNETOM
Avanto (Erlangen, Germany) 1.5-Tesla scanner with a 12-element
phased array cardiac surface coil.19 The imaging protocol included
cine magnetic resonance imaging with steady-state free precession
(SSFP), native T1 mapping,15,20 T2 mapping,21,22 T2*-mapping, and
delayed-enhancement phase-sensitive inversion-recovery pulse se-
quences.23 The scan acquisitions were spatially co-registered and also
included different slice orientations to enhance diagnostic confidence.
Cardiac magnetic resonance was also performed in 50 healthy volun-
teers of similar age and gender in order to obtain local reference values
for myocardial native T1 (Supplementary material online). Patients and
healthy volunteers underwent the same imaging protocol except that
healthy volunteers ,45 years did not receive gadolinium. The coeffi-
cients of variation for native T1 were also measured (Supplementary
material online, Results).
Native T1 maps were acquired in three short-axial slices (basal, mid,
and apical), using an optimized modified look-locker inversion recovery
(MOLLI) T1-mapping investigational prototype sequence15,20 before con-
trast administration (Supplementary material online, Methods;
work-in-progress 448, Siemens Healthcare). TheMOLLI T1 cardiac-gated
acquisition involved three inversion recovery prepared Look-Locker
experiments combined within one protocol.15 The CMR parameters
were: bandwidth 1090 Hz/pixel, flip angle 358, echo time (TE) 1.1 ms,
T1 of first experiment 100 ms, TI increment 80 ms, matrix 192 × 124
pixels, spatial resolution 2.2 × 1.8 × 8.0 mm, slice thickness 8 mm, and
scan time 17 heartbeats. The prototype pulse sequence did not involve
motion correction.
T2 maps were acquired in contiguous short-axis slices covering the
whole ventricle, using an investigational prototype T2-prepared True-
Fisp sequence21,22 (Supplementary material online, Methods). Typical
imaging parameters were: bandwidth 947 Hz/pixel, flip angle 708,
T2 preparations: 0, 24, and 55 ms, respectively, matrix 160 × 105 pixels,
spatial resolution 2.6 × 2.1 × 8.0 mm, and slice thickness 8 mm.
T2*-maps were obtained using an investigational prototype T2* map
sequence acquired in three short-axis slices (basal, mid, and apical). Typ-
ical imaging parameters were: bandwidth 814 (8×) Hz/pixel; flip angle
188; matrix 256 × 115; spatial resolution 2.6 × 1.6 × 10 mm; slice
thickness 8 mm.
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Early gadolinium enhancement (EGE) imaging was acquired 1, 3, 5,
and 7 min post-contrast injection using a TrueFISP readout and fixed in-
version time (TI) of 440 ms. Late gadolinium enhancement images cover-
ing the entire LV were acquired 10–15 min after IV injection of 0.15 mmol/
kg of gadoterate meglumine (Gd2+-DOTA, Dotarem, Guebert S.A.) using
segmented phase-sensitive inversion recovery turbo fast low-angle shot se-
quence.23 Typical imaging parameters were: matrix ¼ 192 × 256, flip
angle ¼ 258, TE ¼ 3.36 ms, bandwidth ¼ 130 Hz/pixel, echo spacing ¼
8.7 ms, and trigger pulse ¼ 2. The voxel size was 1.8 × 1.3 × 8 mm3. In-
version times were individually adjusted to optimize nulling of apparent-
ly normal myocardium (typical values, 200–300 ms).
Cardiac magnetic resonance analyses
The images were analysed on a Siemens work-station by observers with
at least 3 years CMR experience (N.A., D.C., I.M, and S.R.). All of the
images were reviewed by experienced CMR cardiologists (C.B. and
N.T.). Left ventricular dimensions, volumes, and ejection fraction were
quantified using computer-assisted planimetry (syngo MRw, Siemens
Healthcare, Erlangen, Germany). The late gadolinium enhancement
images were analysed for infarct size and microvascular obstruction
by observers (N.A. and I.M.) who were blinded to all of the other
data. In healthy volunteers, the absence of late gadolinium enhancement
was determined qualitatively by visual assessment.
Native T1 mapping: standardized measurements in
myocardial regions of interest
Native T1 mapping is a CMR method providing a parametric colour-
encoded anatomical map in which the T1 value is encoded in each
pixel24 (Figure 1). The native T1map analyses were informed by contem-
porary CMR guidelines.24 Left ventricular contours were delineated
with computer-assisted planimetry on the raw T1 image and copied
onto the colour-encoded spatially co-registered map. Apical segments
were not included because of partial volume effects. Particular care
was taken to delineate regions of interest with adequate margins of sep-
aration from tissue interfaces prone to partial volume averaging such as
between myocardium and blood.19,24,25 Each T1 map image was as-
sessed for the presence of artefacts relating to susceptibility effects,
or cardio-respiratory motion. Each colour map was evaluated against
the original images. When artefacts occurred the affected segments
were not included in the analysis.
In STEMI patients, myocardial T1 values were segmented spatially and
regions of interest were defined as (i) remote myocardium, (ii) injured
myocardium, and (iii) infarct core. The regions of interest were planime-
tered to include the entire area of interest with distinct margins of sep-
aration from tissue interfaces to avoid partial volume averaging. The
remote myocardium region of interest was defined as myocardium
1808 from the affected zone with no visible evidence of infarction, oe-
dema, or wall motion abnormalities (assessed by inspecting correspond-
ing contrast-enhanced T1-weighted, T2-weighted, and cine images,
respectively). The infarct zone region of interest was defined as myocar-
dium with pixel values (T1 or T2) .2 SD from remote myocardium on
T2-weighted CMR.21,22 The hypo-intense infarct core was defined as an
area in the centre of the infarct territory having a mean T1 value of at
least 2 standard deviations (SDs) below the T1 value of the periphery
of the area at risk.21,22 The assessment of T1 maps and adjudication
(present/absent) of a hypo-intense core was performed independently
by D.C.
In healthy volunteers, the mid-ventricular T1 colour-encoded map
was segmented into six equal segments, using the anterior right
ventricular-LV insertion point as the reference point.26 T1 was mea-
sured in each of these segments, and regions of interest were planime-
tered distinct and separate from blood-pool and tissue interfaces. These
segmental values were also averaged to provide one value per subject.
Results are presented as average values for segments and slices.
Infarct definition and size
The presence of acute infarction was established based on abnormalities
in cine wall motion, rest first-pass myocardial perfusion, and delayed-
enhancement imaging in two imaging planes. In addition, supporting
changes on the ECG and coronary angiogramwere also required. Acute
infarction was considered present only if late gadolinium enhancement
was confirmed on both the axial and long-axis acquisitions. The myocar-
dial mass of late gadolinium (grams) was quantified using computer-
assisted planimetry and the territory of infarction was delineated using
a signal-intensity threshold of .5 SDs above a remote reference region
and expressed as a percentage of total LV mass.27 Infarct regions with
evidence of microvascular obstruction were included within the infarct
area and the extent of microvascular LV ventricular mass was also
measured. The measurements of infarct size were performed by I.M.
and N.A.
Microvascular obstruction
Microvascular obstruction was defined as a dark zone on EGE imaging 1,
3, 5, and 7 min post-contrast injection that remained present within an
area of LGE at 15 min. Identification of microvascular obstruction was
performed independently by I.M. and N.A.
Area-at-risk
Area-at-risk was defined as LV myocardium with pixel values (T2) .2
SDs from remote myocardium.4,21,22,28 – 30 In order to assess the
area-at-risk, the epi- and endocardial contours on the last correspond-
ing T2-weighted raw image with an echo time of 55 ms were planime-
tered.21 Contours were then copied to the computed T2 map and
corrected when necessary by consulting the SSFP cine images.
Myocardial salvage
Myocardial salvage was calculated by subtraction of per cent infarct size
from per cent area at risk.4,30,31 The myocardial salvage index was calcu-
lated by dividing the myocardial salvage area by the initial area at risk.
Adverse remodelling
Adverse remodelling was pre-defined as an increase in LV end-diastolic
volume ≥20% at 6 months from baseline.3
Myocardial haemorrhage
On the T2* maps, a region of reduced signal intensity within the in-
farcted area, with a T2* value of ,20 ms32 – 35 was considered to
confirm the presence of myocardial haemorrhage.
Electrocardiogram
A 12-lead ECG was obtained before coronary reperfusion and 60 min
afterwards. The extent of ST-segment resolution on the ECG assessed
60 min after reperfusion compared with the baseline ECG before reper-
fusion17 was expressed as complete (≥70%), incomplete (30% to
,70%), or none (≤30%).
Laboratory analyses
The acquisition of the ECGs and blood samples for biochemical and
hematologic analyses are described in Supplementary material online,
Methods.
D. Carrick et al.1046
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Pre-specified health outcomes
We pre-specified adverse health outcomes that are pathophysiological-
ly linked with STEMI. The primary composite outcome was (i) all-cause
death or first heart failure hospitalization (Supplementary material on-
line, Methods). Other health outcomes included major adverse cardiac
events (MACEs) defined as cardiac death, non-fatal MI, or hospitaliza-
tion for heart failure.
Research staff screened for events from enrolment by checking
the medical records and by contacting patients and their primary
and secondary care physicians, as appropriate with no loss to follow-up
(Figure 2). Each serious adverse event (SAE) was reviewed by a cardiolo-
gist who was independent of the research team and blinded to all of the
clinical and CMR data. The SAEs were defined according to standard
guidelines36,37 (Supplementary material online, Methods) and categor-
ized as having occurred either during the index admission or post-
discharge. All study participants were followed up for a minimum of
18 months after discharge. The median duration of follow-up was of
845 days [post-discharge censor duration (range) 598–1098 days].
Statistical analyses
The sample size calculation is described in Supplementary material on-
line, Methods. We estimated that at least 30 MACE events would occur
based on a conservative estimate of the event rate (10–12%) at 18
months.
Categorical variables are expressed as number and percentage of pa-
tients. Most continuous variables followed a normal distribution and are
Figure 1 Three patients with acute ST-elevation myocardial infarction treated by primary PCI and with the same anti-thrombotic therapies,
including aspirin, clopidogrel, heparin, and intravenous tirofiban. Each patient had normal thrombolysis in myocardial infarction Grade 3 flow
at the end of PCI. Cardiac magnetic resonance imaging was performed for each patient 2 days later. (A) Patient with no T1 hypo-intense infarct
core and nomicrovascular obstruction.Native T1 within the injury zone (middle) measured 1211 ms. Acute infarct size revealed by late gadolinium
enhancement (right) was 22.2%. The left ventricular ejection fraction and left ventricular end-diastolic volume were 55.2% and 143.1 mL, respect-
ively. Analysis of the repeat magnetic resonance imaging scan after 6 months follow-up indicated that the final infarct size was 15.6% of left ven-
tricular mass and the left ventricular end-diastolic volume had reduced to 103.0 mL. This patient had an uncomplicated clinical course. (B) Patient
with both T1 hypo-intense infarct core and microvascular obstruction. T1mapping (middle) revealed a hypo-intense region within the infarct core,
corresponding to the area of microvascular obstruction on contrast-enhanced magnetic resonance imaging (right). Native T1 within the infarct
core measured 1036 ms, which was substantially lower than the T1 value measured at the periphery of the infarct zone (1193 ms). Acute infarct
size revealed by late gadolinium enhancement (right) was 33.0%. Microvascular obstruction depicted as the central dark zone within the infarct
territory was 3.6% of left ventricular mass. The left ventricular ejection fraction and end-diastolic volume were 45.8% and 199.3 mL, respectively.
The final infarct size at 6 months was 22.6% of left ventricular mass and the left ventricular end-diastolic volume had increased to 221.8 mL. This
patient was re-hospitalized for new onset heart failure during follow-up.
Infarct core native T1 and prognosis post-STEMI 1047
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therefore presented as means together with SD. Those variables that
did not follow a normal distribution are presented as medians with
interquartile range. Differences in continuous variables between groups
were assessed by the Student’s t-test or analysis of variance (ANOVA)
for continuous data with normal distribution, otherwise the non-
parametric Wilcoxon rank sum test or Kruskal–Wallis test. Differences
in categorical variables between groups were assessed using a x2 test or
Fisher’s test, as appropriate. Correlation analyses were Pearson or
Spearman tests, as indicated. Random effects models were used to com-
pute inter- and intra-rater reliability measures [intra-class correlation
coefficient (ICC)] for the reliability of infarct core native T1 values mea-
sured independently by 2 observers in 12 randomly selected patients
from the cohort.
Univariable andmultivariable linear regressionmethods to identify as-
sociates of T1 values for (i) remote myocardium, (ii) injured myocar-
dium within the area at risk, (iii) infarct core in all patients, and (iv) in
Figure 2 Flow diagram of the cohort study.
D. Carrick et al.1048
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/37/13/1044/2398329 by U
niversity Library user on 01 M
ay 2019
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical and angiographic characteristics of 288 ST-elevation myocardial infarction patients who had cardiac magnetic resonance with evaluable maps for
myocardial native T1 magnetization, including the subset of patients with an infarct core revealed by native T1 (all and categorized by tertiles of native T1)
Characteristicsa All patients
(n5 288)
Patients with a native T1
infarct core (n5 160) (56%)
Patients with a native T1 infarct core grouped by tertile of infarct core zone
native T1 (ms) at baseline
P-value
T1 core ≤973 ms
(n 5 54) (33%)
974 <T1 core ≤1010 ms
(n 5 53) (33%)
T1 core >1010 ms
(n 5 53) (33%)
Age (years) 59 (11) 59 (11) 59 (11) 57 (11) 61 (11) 0.238
Male sex, n (%) 211 (73) 123 (77) 46 (85) 37 (70) 40 (76) 0.144
BMI (kg/m2) 29 (5) 29 (5) 29 (4) 29 (5) 28 (5) 0.674
Medical history
Hypertension, n (%) 93 (32) 57 (36) 17 (32) 21 (40) 19 (36) 0.684
Current smoking, n (%) 177 (62) 100 (62) 32 (59) 34 (64) 34 (64) 0.858
Hypercholesterolaemia, n (%) 82 (28) 44 (28) 12 (22) 17 (32) 15 (28) 0.527
Diabetes mellitus,b n (%) 32 (11) 20 (12) 7 (13) 7 (13) 6 (11) 1.000
Previous angina, n (%) 34 (12) 21 (13) 8 (15) 4 (8) 9 (17) 0.304
Previous myocardial infarction, n (%) 23 (8) 15 (9) 5 (9) 3 (6) 7 (13) 0.415
Previous PCI, n (%) 16 (6) 14 (9) 4 (7) 3 (6) 7 (13) 0.414
Presenting characteristics
Heart rate (bpm) 78 (17) 78 (16) 80 (16) 79 (16) 76 (17) 0.401
Systolic blood pressure (mmHg) 136 (24) 136 (22) 137 (24) 140 (23) 131 (19) 0.095
Diastolic blood pressure (mmHg) 79 (14) 80 (14) 82 (14) 83 (13) 76 (13) 0.010
Time from symptom onset to reperfusion (min) 174 (120, 311)a 188 (125, 388) 223 (145, 406) 163 (113, 313) 198 (128, 257) 0.268
Ventricular fibrillationc, n (%) 20 (7) 150 (94) 3 (6) 2 (4) 5 (9) 0.518
Heart failure, Killip class at presentation, n (%)
I 205 (71%) 101 (63) 29 (54%) 38 (72%) 34 (64%)
II 64 (22%) 43 (27) 15 (28%) 14 (26%) 14 (26%) 0.059
III/IV 19 (7) 16 (10) 10 (18) 1 (2) 5 (9)
ECG
ST segment elevation resolution post-PCI, n (%)
Complete, ≥70% 129 (45) 55 (35) 15 (28) 21 (40) 19 (36)
Incomplete, 30% to ,70% 115 (40) 74 (46) 27 (50) 23 (44) 24 (45) 0.715
None, ≤30% 43 (15) 30 (19) 12 (22) 8 (15) 10 (19)
Reperfusion strategy, n (%)
Primary PCI 268 (93) 148 (92) 49 (91) 49 (92) 50 (94)
Rescue PCI (failed thrombolysis) 13 (4) 10 (6) 4 (7) 3 (6) 3 (6) 1.000
Successful thrombolysis 7 (2) 2 (1) 1 (2) 1 (2) 0 (0)
Continued
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Table 1 Continued
Characteristicsa All patients
(n5 288)
Patients with a native T1
infarct core (n5 160) (56%)
Patients with a native T1 infarct core grouped by tertile of infarct core zone
native T1 (ms) at baseline
P-value
T1 core ≤973 ms
(n 5 54) (33%)
974 <T1 core ≤1010 ms
(n 5 53) (33%)
T1 core >1010 ms (n 5
53) (33%)
Coronary angiography
Number of diseased arteries,d n (%)
1 156 (54) 89 (56) 156 (54) 156 (54) 156 (54)
2 89 (29) 44 (28) 90 (31) 90 (31) 90 (31) 0.436
3 42 (15) 24 (15) 42 (15) 42 (15) 42 (15)
LM 6 (2) 3 (2) 0 (0) 2 (4) 1 (2)
Culprit artery, n (%)
LAD 108 (38) 60 (38) 22 (41) 19 (36) 19 (36)
LCX 51 (18) 31 (19) 10 (18) 12 (23) 9 (17) 0.915
RCA 129 (45) 69 (34) 22 (41) 22 (42) 25 (47)
TIMI coronary flow grade pre-PCI, n (%)
0/1 208 (72) 135 (84) 49 (91) 39 (74) 47 (89)
2 52 (18) 27 (13) 5 (9) 11 (21) 5 (9) 0.085
3 28 (10) 4 (2) 0 (0) 3 (6) 1 (2)
TIMI coronary flow grade post-PCI, n (%)
0/1 3 (1) 2 (1) 0 (0) 1 (2) 1 (2)
2 13 (4) 8 (5) 3 (6) 3 (6) 2 (4) 0.959
3 272 (94) 150 (94) 51 (94) 49 (92) 50 (94)
Medical therapy
ACE-I or ARB 285 (99) 159 (.99) 54 (100) 53 (100) 52 (98) 0.663
b-Blocker 278 (96) 158 (99) 53 (98) 52 (98) 53 (100) 1.000
Initial blood results on admission
C-reactive protein, (mg/L), median (IQR), range 3.0 (2.0–7.0)
0–265.0
4.0 (2.0, 8.0)
1.0–265
3.5 (2.0–11.0)
1.0–125.0
3.0 (1.0–6.2)
1.0–92.0
4.0 (2.0–7.0)
1.0–265.0
0.696
Leucocyte cell count (×109 L) 12.4 (3.5) 12.8 (3.6) 12.9 (3.5) 13.3 (3.5) 12.3 (3.6) 0.310
Neutrophil count (×109 L) 9.6 (3.2) 10.1 (3.3) 10.0 (3.4) 10.6 (3.4) 9.6 (3.0) 0.244
Monocytes (×109 L) 0.4 (0.4) 0.9 (0.4) 1.0 (0.4) 0.9 (0.3) 0.9 (0.5) 0.485
NT-proBNP (pg/mL) 824 (350, 1642) 1103 (628, 1849) 1456 (702, 2455) 980 (565, 1637) 1021 (529, 1436) 0.354
Missing data: heart rate, n ¼ 1; time from symptom onset to reperfusion, n ¼ 20; ST-segment resolution, n ¼ 1; CRP, n ¼ 7; leucocyte count, n ¼ 1. The patients are grouped according to tertile of T1 in hypo-intense core at baseline.
ACE-I or ARB, angiotensin converting enzyme inhibitor or angiotensin receptor blocker; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; RCA, right coronary artery; TIMI,
thrombolysis in myocardial infarction grade; PCI, percutaneous coronary intervention. Killip classification of heart failure after acute myocardial infarction: class I—no heart failure, class II—pulmonary rales or crepitations, a third heart sound,
and elevated jugular venous pressure, class III—acute pulmonary oedema, and class IV—cardiogenic shock.
aData are reported as mean (SD), median (IQR), or N (%) as appropriate. P-values have been obtained from a one-way ANOVA or Fisher test. Thrombolysis in myocardial infarction flow grades pre- and post-PCI were grouped 0/1 vs. 2/3 for this
analysis.
bSuccessfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure.
cDiabetes mellitus was defined as a history of diet-controlled or treated diabetes.
dMulti-vessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter, by visual assessment and whether or not there was left main stem involvement. The blood results on
admission and their changes during the first 2 days after admission are described in Supplementary material online, Table S1.
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Table 2 Comparison of cardiac magnetic resonance findings at baseline in 288 ST-elevation myocardial infarction survivors and 6-month cardiac magnetic
resonance findings in 278 ST-elevation myocardial infarction patients
Characteristics* All patients Patients with a native
T1 infarct core
Patients with a native T1 infarct core grouped by tertile of infarct core zone
native T1 (ms) at baseline
P-value
All patients (n5 288) Hypo-intense core
(n5 160)
≤973 ms (n5 54) 974 <T1 core ≤1014 ms (n 5 53) >1014 ms (n5 53)
CMR findings 2 days post-MI
LV ejection fraction (%) 55 (10) 52 (9) 52 (10) 51 (8) 53 (10) 0.418
LV end-diastolic volume, ml
Men 162 (33) 168 (147, 187) 168 (22) 169 (36) 166 (30) 0.900
Women 124 (25) 125 (113, 145) 122 (30) 134 (26) 126 (21) 0.497
LV end-systolic volume (mL)
Men 73 (55, 94) 79 (64, 98) 75 (64, 94) 81 (74, 103) 76 (60, 100) 0.496
Women 53 (41, 66) 64 (50, 69) 64 (57, 71) 66 (57, 70) 56 (45, 65) 0.383
LV mass (g)
Men 142 (124, 159) 145 (130, 166) 149 (135, 170) 143 (126, 159) 141 (130, 160) 0.526
Women 97 (84, 108) 101 (89, 124) 103 (92, 113) 109 (93, 132) 97 (83, 101) 0.113
Oedema and infarct characteristics
Area at risk, % LV mass 32 (12) 40 (11) 37 (11) 35 (10) 36 (11) 0.482
Infarct size, % LV mass 16 (7, 27) 25 (16, 32) 25 (18, 34) 27 (18, 32) 22 (16, 32) 0.386
Myocardial salvage, % of LV mass 18 (12, 24) 17 (12, 23) 18 (12, 24) 17 (10, 22) 16 (13, 22) 0.546
Myocardial salvage index, % of LV mass 62 (44, 84) 49 (36, 62) 50 (40, 62) 46 (30, 62) 50 (40, 63) 0.590
Late microvascular obstruction present, n (%) 145 (50) 23 (14) 49 (91) 45 (85) 43 (81) 0.356
Late microvascular obstruction, % LV mass 0.1 (0.0, 3.5) 2.7 (0.8, 7.5) 5.2 (1.7, 10.5) 2.7 (0.9, 7.1) 1.7 (0.3, 4.7) 0.005
Myocardial haemorrhage, n (%)* 96 (40) 94 (67) 34 (76) 35 (70) 25 (54) 0.086
Myocardial native T1 values
T1 remote myocardium (all subjects) (ms) 961 (25) 964 (26) 958 (28) 962 (20) 972 (28) 0.014
Men 959 (25) 962 (26) 955 (29) 959 (19) 973 (26) 0.004
Women 968 (25) 969 (26) 969 (22) 969 (22) 968 (36) 0.992
T1 infarct zone (ms) 1097 (52) 1093 (52) 1052 (37) 1088 (33) 1140 (22) ,0.001
T1 hypo-intense infarct core (ms) 997 (57) 997 (57) 938 (30) 995 (12) 1060 (37) ,0.001
Myocardial native T2 values
T2 infarct core (n ¼ 171, ms) 54 (5) 54 (5) 52 (4) 53 (4) 56 (5) ,0.001
CMR findings 6 months post-MI (n ¼ 267)
LV ejection fraction at 6 months (%) 63 (57, 69) 60 (53, 65) 59 (53, 65) 59 (54, 64) 61 (54, 68) 0.542
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patients without late microvascular obstruction are described in Supple-
mentary material online, Methods.
Receiver-operating curve (ROC), Kaplan–Meier, and Cox propor-
tional hazards methods were used to identify potential clinical predic-
tors of all-cause death/heart failure events and MACE, including
patient characteristics, CMR findings, and native T1. The net reclassifica-
tion improvement (NRI) was calculated as described by Pencina et al.38
All P-values are two sided. P-value of,0.05 should be interpreted ex-
ploratively. Statistical analyses were performed using R version 2.15.1 or
SAS v 9.3, or higher versions of these programs.
Results
Of 343 STEMI patients referred for emergency reperfusion therapy,
300 underwent serial CMR at 1.5 T 2.2+ 1.9 days and 6 months
after hospital admission (Figure 2). Two hundred and ninety-two
STEMI patients had a T1-map acquisition and 288 (99%) had evalu-
able T1 data (Figure 2). Cardiac magnetic resonance follow-up at 6
months was achieved in 267 (93%) of the patients and the reasons
for non-attendance are summarized in Figure 2. Information on vital
status and SAEs were available in all (100%) of the 288 participants.
Patient characteristics
Table 1 shows the characteristics of the patients, including the
patients with a hypo-intense infarct core revealed by native T1 map-
ping [n ¼ 160 (56%), grouped by thirds of native T1]. The C-reactive
protein and leucocyte results are described in Supplementary
material online, Table S1. The characteristics of those patients
with missing CMR data at 6 months are described in Supplementary
material online, Table S2.
Left ventricular function and pathology
Initial cardiac magnetic resonance findings following
hospital admission
The CMR findings are summarized in Table 2 and case examples are
shown in Figure 2. At baseline, the mean (SD) myocardial infarct size
was 18 (14) % of LV mass. The average infarct core native T1 (997
(57)) was higher than native T1 in the remote myocardium 961
(25) ms; P, 0.01] but lower than native T1 in the area at risk
(1097 (52) ms; P, 0.01). The ICC for T1 core is described in
Supplementary material online, Results.
Baseline associates of infarct core native
T1 (Hypothesis 1)
Native T1 in the infarct core was inversely associated with thromb-
olysis in myocardial infarction (TIMI) coronary flow grades at the
end of emergency PCI, Killip class and neutrophil count at initial
presentation (all P, 0.04), independent of left ventricular ejection
fraction (LVEF), LV end-diastolic volume, or infarct size (Table 3).
Infarct core native T1 (ms) was univariably associated with infarct
core T2 (ms) (r ¼ 0.42; P, 0.001).
Relationships for native T1 infarct core vs. infarct pathology, in-
cluding infarct core T2, myocardial haemorrhage, and microvascular
obstruction and 137 (86%) STEMI patients with a hypo-intense na-
tive T1 infarct core also had microvascular obstruction. In contrast,
only 6.3% of those without hypo-intense infarct core had late micro-
vascular obstruction. The negative- and positive predictive values of
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native T1 infarct core for T2 infarct core, myocardial haemorrhage,
EGE, and microvascular obstruction are summarized in Supplemen-
tary material online, Table S2.
Infarct core tissue characteristics as a
marker of subsequent left ventricular
remodelling (Hypothesis 2)
At 6 months, LV end-diastolic volume increased on average (SD) by
5 (25) ml in 262 patients with evaluable data (Table 2). Adverse re-
modelling occurred in 30 (12%) patients and 23 (77%) of these pa-
tients had a hypo-intense native T1 core at baseline. Infarct core
native T1 (ms) was not associated with change in LV end-diastolic
volume at follow-up (P ¼ 0.531). In multivariable regression, native
T1 (ms, continuous) within the hypo-intense core was inversely
associated with adverse remodelling (Table 4).
In a sensitivity analysis, the occurrence of a hypo-intense core
within the infarct zone on T1 mapping was associated with the
odds ratio for being in the top quarter of an increase in LV
end-diastolic volume at 6 months (native T1 core to predict Q4
(n ¼ 66) vs. Q1–Q3 (n ¼ 196) (n ¼ 26 missing); odds ratio 0.994
(0.987, 0.999); P ¼ 0.048).
Native T1 infarct core, microvascular obstruction,
and left ventricular outcomes at 6 months
The relationships for infarct core native T1 (binary and continuous),
T2 core (binary and continuous), microvascular obstruction (binary,
% LV mass), and myocardial haemorrhage for LV outcomes, includ-
ing LV end-diastolic volume and LV ejection fraction, are shown in
Table 5. The presence of a hypo-intense infarct core disclosed by
native T1 and native T2, the presence and amount of microvascular
obstruction, and the occurrence of myocardial haemorrhage, were
consistently associated with LV outcomes. Native T1 (ms) was not
associated with LV volumes at follow-up, and there was no evidence
of non-linearity between infarct core T1 (ms) and LV outcomes.
Infarct core native T1 early post-MI was associated with the con-
centration of NT-proBNP, a biochemical measure of LV remodel-
ling, at 6 months independent of LV end-diastolic volume at
baseline (Supplementary material online, Results).
Infarct core tissue characteristics and
health outcomes (Hypothesis 3)
All 288 patients had long-term follow-up data completed. Thirty
(10.4%) patients died or experienced a heart failure event. These
events included 5 cardiovascular deaths, 3 non-cardiovascular
deaths, and 22 episodes of heart failure (Killip Class 3 or 4 heart fail-
ure (n ¼ 20) or defibrillator implantation n ¼ 2). Thirteen (4.5%)
patients died or experienced a first heart failure hospitalization post-
discharge, and 8 (61.5%) of these patients had a hypo-intense infarct
core at baseline.
Native T1 values (ms) within the hypo-intense infarct core
(n ¼ 160 STEMI patients) were inversely associated with the risk
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Table 3 Associates of infarct core native T1 time (for a 10 ms difference) in 160 ST-elevation myocardial infarction
survivors with infarct core pathology revealed by native T1 mapping with cardiac magnetic resonance 2 days
post-myocardial infarction
Multiple stepwise regression (for a 10 ms difference in infarct core T1) Coefficient (95% CI) P-value
A. Including patient characteristics and angiographic data*
Systolic blood pressure at initial angiography (mmHg) 20.05 (20.09, 20.01) 0.007
Killip Class 3 or 4 23.84 (26.87, 20.80) 0.014
TIMI flow Grade 2 or 3 post-PCI 27.51 (215.42, 0.40) 0.063
B. Including patient characteristics, angiographic data, and minimum neutrophil count*
Systolic blood pressure at initial angiography (mmHg) 20.05 (20.09, 20.01) 0.015
Killip Class 3 or 4 23.39 (26.45, 20.33) 0.030
TIMI flow Grade 2 or 3 at the end of PCI 29.77 (217.67, 21.87) 0.005
Minimum neutrophil count (×109 L) 20.50 (20.86, 20.15) 0.005
C. Including patient characteristics, angiographic data, minimum neutrophil count, and T2 core (1 ms)a
T2 core (1 ms) 0.50 (0.32, 0.67) ,0.001
Neutrophils 20.39 (20.71, 0.07) 0.016
Gender (male) 22.32 (24.25, 0.39) 0.019
SBP 20.03 (20.07, 0.00) 0.059
TIMI 2/3 post-PCI 25.46 (212.62, 1.70) 0.134
The coefficient (95% CIs) indicates the magnitude and direction of the effect of the patient characteristic (binary or continuous) on the infarct core T1 (ms). For example, in models
A and B, on average, infarct core native T1 (10 ms difference) is 0.50 lower for each 1 mmHg increase in SBP.
aThe clinical and angiographic characteristics that were assessed are listed in Table 1. The univariable associates with native T1 in the infarct core are described in Supplementary
material online, Results. Separate multivariable analyses were performed for (A) patient characteristics and angiographic data and (B) CMR data. Cardiac magnetic resonance
parameters, which were all highly correlated with one another, were included separately in multiple stepwise regression models with patient characteristics and angiographic data
to reduce multi-collinearity.
Similar results were obtained when area at risk, LV ejection fraction, LV end-systolic volume, and infarct size were included. Maximum leucocyte count (P ¼ 0.053) and maximum
monocyte count (P ¼ 0.034) remained associates of infarct core native T1 after adjustment for LV end-diastolic volume. Similar results were also obtained in the multivariable
model with LV end-diastolic volume for minimum leucocyte count (P ¼ 0.011).
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of all-cause death or first hospitalization for heart failure post-
discharge (for a 10 ms increase in native T1: hazard ratio 0.730,
95% confidence interval (CI) 0.617, 0.863; P, 0.001) including after
adjustment for LVEF at baseline, infarct core T2 (10 ms difference),
and myocardial haemorrhage (Figure 3; Table 6). Infarct core T1
retained its prognostic significance over and above infarct core T2
andmyocardial haemorrhage (Table 6, models C–F). The net reclas-
sification index for the inclusion of infarct core native T1 (10 ms) in a
multivariable prognostic model for all-cause death or heart failure
post-discharge was 1.129 (95% CI 0.516, 1.742); P, 0.001)
(Table 6). Using ROC analysis, the C-index for infarct core native
T1 for all-cause death or heart failure was 0.806. The C-indexes
for the prognostic model without and with infarct core native T1
(ms) were 0.715 and 0.931, respectively.
Prognostic importance of infarct core native T1:
comparisons with microvascular obstruction and longer
term health outcomes
In univariate Cox models for infarct core native T1 (ms), native T1
core (binary), T2 core (ms), T2 core (binary), myocardial haemor-
rhage and the presence (binary) and amount of microvascular
obstruction (% LV mass), only infarct core native T1 (ms)
(P, 0.001) and the amount of microvascular obstruction (% LV
mass) (P, 0.001) were associated with all-cause death or first heart
failure hospitalisation after discharge. In a post-hoc analysis stimu-
lated by peer review, the odds ratio for infarct core T1 (10 ms)
at baseline for the occurrence of all-cause death, heart failure hos-
pitalisation or adverse LV remodelling was 0.92 (95% CI 0.85, 0.99),
P ¼ 0.0312. The inverse relationships between infarct core native
T1 (ms) and LV surrogate and adverse health outcomes were rea-
sonably linear, and there was no cut-off value for infarct core T1
(ms) for these outcomes.
Discussion
The main findings of our study are (i) native T1 mapping revealed
without an intravenous contrast agent resulted in evaluable scans
in 96% of STEMI survivors 2 days post-MI; (ii) acute culprit coronary
artery blood flow and circulating measures of systemic inflammation
at the time of the hospital admission weremultivariable associates of
native T1 within the hypo-intense infarct core revealed by T1 map-
ping 2 days later; (iii) native T1 values (ms) within the infarct core
were clinically meaningful since they were independently associated
with adverse remodelling, NT-proBNP concentrations at 6 months,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Multivariable associates of adverse LV remodelling revealed by cardiac magnetic resonance in ST-elevation
myocardial infarction survivorsa after 6 months follow-up
Multivariable associations Odds ratio (95% CI) P-value
A. Patient and angiographic characteristics
Native T1 infarct core, per 10 ms 0.91 (0.82, 1.00) 0.061
Current smoking 5.27 (1.07, 26.00) 0.041
Sustained ventricular arrhythmia 16.06 (1.67, 154.43) 0.016
Incomplete ST-segment resolution 3.29 (0.85, 12.78) 0.085
B. Patient and angiographic characteristics and infarct core native T2
Native T1 infarct core, per 10 ms 0.91 (0.81, 1.01) 0.073
Native T2 infarct core, per 10 ms 1.01 (0.28, 3.67) 0.987
Current smoking 4.99 (0.99, 25.06) 0.051
Sustained ventricular arrhythmia 15.26 (1.57, 148.71) 0.019
Incomplete ST-segment resolution 3.18 (0.81, 12.43) 0.097
C. Patient and angiographic characteristics and myocardial haemorrhage
Native T1 infarct core, per 10 ms 0.90 (0.81, 1.01) 0.070
Myocardial haemorrhage 0.57 (0.14, 2.41) 0.449
Current smoking 4.78 (0.83, 27.52) 0.080
Sustained ventricular arrhythmia 11.70 (0.94, 144.88) 0.055
Incomplete ST-segment resolution 3.68 (0.90, 15.02) 0.069
The odds ratio (95% CIs) indicates the magnitude and direction for adverse LV remodelling. For a 10 ms increase in native T1, the odds ratio for adverse LV remodelling reduced
(0.91 (0.82, 1.00); P ¼ 0.061). For a 1 ms increase in native T1, the odds ratio for adverse LV remodelling reduced [0.99 (0.98, 1.00); P ¼ 0.061].
aTwenty clinical characteristics at baseline that were univariable associates of adverse LV remodelling at 6 months post-MI were included in the multivariable model and these
univariable associates are described in Supplementary material online, Results. Two hundred and sixty-seven STEMI patients had CMR at 6 months and baseline and 23 of these
patients had missing data of at least one of the univariable characteristics that were included in this multivariable model. C-statistic [area-under-the-curve (AUC)] for the
multivariable model in 244 subjects but not including native T1 core: 0.95; C-statistic (AUC) for the model (above) including infarct core native T1 (n ¼ 136): 0.81; net
reclassification index for incremental addition of T1 core to the model: 0.31, P ¼ 0.184.
When the multivariable model for adverse remodelling included infarct size, the AUCwithout native T1 core (continuous, ms) was 0.823 and the AUCwith T1 core values included
was 0.857. Inclusion of native T1 core values neither increased nor reduced the predictive value of this model (net reclassification index P ¼ 0.16).
There was no threshold for native T1 core value in the infarct core in relation to its association with LV outcomes at baseline or during follow-up.
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Table 5 The univariable relationships for infarct core characteristics revealed by native T1 and microvascular
obstruction for LV outcomes at baseline and during follow-up in 288 ST-elevation myocardial infarction patients
LVEDV at
baseline
LVEDV at 6
months
LVEF at
baseline
LVEF at
follow-up
T1 core (per 10 ms) Standardized b 20.042 20.035 0.151 0.055
P-value 0.596 0.520 0.057 0.485
T1 core (binary) b 16.410 13.80 26.642 24.652
P-value ,0.0001 ,0.0001 ,0.0001 ,0.0001
T2 core (per 10 ms) Standardized b 0.035 0.057 0.159 20.033
P-value 0.653 0.282 0.037 0.586
T2 core (binary) b 15.538 12.875 26.542 24.494
P-value ,0.001 ,0.0001 ,0.0001 ,0.0001
Myocardial haemorrhage (T2* core,
binary)
b 17.205 16.811 26.374 25.769
P-value ,0.0001 ,0.0001 ,0.0001 ,0.0001
Microvascular obstruction (% of LV mass) Standardized b 0.186 0.209 20.443 20.283
P-value 0.002 ,0.0001 ,0.0001 0.004
Microvascular obstruction (binary) b 15.853 12.454 26.620 24.464
P-value ,0.001 ,0.0001 ,0.0001 ,0.0001
The relationships for infarct core native T1 relaxation time (per 10 ms), native T1 infarct core (binary), and the presence and the amount of microvascular obstruction (n ¼ 145
STEMI patients) with LV outcomes are summarized by P-values and, for continuous predictors, standardized regression coefficients or odds ratios per SD increase in native T1 (ms)
or extent of microvascular obstruction (% of LV mass). Models with follow-up data are adjusted for baseline. Binary predictors are summarized by P-values and unstandardized
regression coefficients or odds ratios (listed beneath table).
The odds ratio (P-values) for adverse remodelling and infarct core characteristics are: native T1 core (per 10 ms): 0.939, P ¼ 0.122; native T1 core (present/absent): 2.692, P ¼
0.016; T2 core (present/absent): 2.874, P ¼ 0.026; myocardial haemorrhage (present/absent): 2.556, P ¼ 0.025; microvascular obstruction (% LV mass): 1.112, P ¼ 0.004;
microvascular obstruction (present/absent): 1.883, P ¼ 0.115.
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction.
Figure 3 Kaplan–Meier survival curves for 160 ST-elevation myocardial infarction patients grouped according to the native T1 value in the
infarct core with patients grouped by thirds (lowest T1 tertile vs. tertiles 2 and 3) and all-cause death or first heart failure hospitalization
(n ¼ 13) after discharge from hospital to the end of follow-up [censor time 839 (598–1099) days]. Infarct core native T1 values in the lowest
tertile were associated with all-cause death or heart failure hospitalization.
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and all-cause death or heart failure hospitalization post-discharge
during longer term follow-up; (iv) compared with infarct core T2
or myocardial haemorrhage revealed by T2* mapping, infarct core
T1 was more consistently associated with LV surrogate outcomes
and all-cause death or heart failure hospitalization (Table 6), implying
T1 core is more closely linked with infarct pathology; (v) compared
with microvascular obstruction revealed by contrast-enhanced
CMR, a hypo-intense infarct core revealed by T1 mapping had simi-
lar prognostic significance for LV outcomes at 6 months and for
post-discharge cardiac events including all-cause mortality and heart
failure hospitalization in the longer term (Tables 5 and 6). Finally, our
paper adds to the emerging literature on the prognostic value of
quantitative native T1 CMR39 and reaffirms the prognostic import-
ance of MVO post-STEMI.3
The results of this study extend what is known about infarct core
pathology, and also provide a potential mechanistic explanation. In-
farct size1,2 and pathology, including microvascular obstruction,3
haemorrhage,5 and salvage,4 predict cardiac morbidity and mortality
post-MI. These pathologies are revealed by contrast-enhanced
CMR, and until recently, the assessment of infarct tissue without
an intravenous contrast agent has been limited to T2-weighted
and T2* imaging of myocardial haemorrhage.5,11,29,40,41 T1-mapping
methods, including MOLLI15,20 and shMOLLI,42,43 can now be inte-
grated into clinical CMR protocols. Previous studies have assessed
myocardial native T1 in experimental MI models ex vivo,8,10
in vivo,11 or in proof-of-concept clinical studies involving much smal-
ler numbers of MI patients.9,12–15 Our study extends these findings
in a much larger STEMI cohort and provides new evidence that
native T1 core is more reflective of the severity of infarct injury
and its prognostic importance than infarct core T2 and potentially
also myocardial haemorrhage.
We also compared infarct core pathology delineated by native T1
mapping with microvascular obstruction, which is an established
prognostic CMR biomarker post-MI.3 Native T1 mapping is ob-
tained without the use of an intravenous gadolinium-based contrast
agent whereas microvascular obstruction is revealed by CMR
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Table 6 Relationships for infarct core T1 and T2 relaxation times (10 ms) revealed by cardiac magnetic resonance at
baseline in 160 ST-elevationmyocardial infarction patients with an infarct core and all-cause death or first hospitalization
for heart failure post-discharge [median (range) follow-up duration of 841 (723–945) days]
Associations Hazard ratio (95% CI) P-value
Univariable associations
Infarct core native T1 (for a 10 ms difference) 0.730 (0.617, 0.863) <0.001
Myocardial haemorrhage 2.488 (0.814, 7.609) 0.110
LVEF at baseline (for a 1% difference) 0.934 (0.885, 0.985) 0.013
Peak log eosinophil count (×109/L) 0.617 (0.432, 0.881) 0.008
Model A
Infarct core native T1 (for a 10 ms difference) 0.744 (0.627, 0.883) <0.001
LVEF at baseline (1% difference) 0.938 (0.883, 0.996) 0.036
Model B
Infarct core native T1 (for 10 ms difference) 0.737 (0.621, 0.875) <0.001
Peak log eosinophil count (1 ×109/L) 0.728 (0.476, 1.114) 0.144
Univariable associations
Infarct core native T2 (for a 10 ms difference) 0.186 (0.032, 1.094) 0.063
Model C
Infarct core native T2 (for a 10 ms difference) 0.244 (0.039, 1.528) 0.132
LVEF at baseline (for a 1% difference) 0.932 (0.870, 0.998) 0.044
Model D
Infarct core native T2 (for 10 ms difference) 0.203 (0.034, 1.297) 0.093
Peak log eosinophil count (×109/L) 0.681 (0.460, 1.007) 0.054
Model E
Infarct core T1 (for 10 ms difference) 0.738 (0.624, 0.873) <0.001
Myocardial haemorrhage 1.965 (0.229, 16.864) 0.538
Model F
Infarct core T1 (for 10 ms difference) 0.752 (0.634, 0.893) 0.001
Infarct core T2 (for a 10 ms difference) 0.428 (0.068, 2.683) 0.365
Myocardial haemorrhage 1.485 (0.159, 13.879) 0.729
Thirteen (8.1%) patients experienced all-cause death or heart failure hospitalization post-discharge. Given the limited number of adverse events, the models were specified to
assess the prognostic relationships of infarct core native T1 vs. circulating markers of systemic inflammation, LV function, LV volume, and infarct characteristics that were measured
at approximately the same time 2 days after hospital admission.
LVEF, left ventricular ejection fraction. Infarct core T1 (10 ms difference) is highlighted in bold.
D. Carrick et al.1056
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/37/13/1044/2398329 by U
niversity Library user on 01 M
ay 2019
imaging of EGE and LGE after intravenous contrast administration.
We observed a high degree of concordance between the occur-
rence of a hypo-intense infarct core depicted by native T1 CMR
(56%) and microvascular obstruction (50%) as revealed by
contrast-enhanced CMR. Although both a native T1 core and
microvascular obstruction are depicted as a hypo-intense corewith-
in the hyperintense infarct zone (Figure 2), the physics of the CMR
techniques is entirely different. A hypo-intense infarct core depicted
by non-contrast native T1 mapping is due to local destruction of the
T1 magnetization signal. On the other hand, microvascular obstruc-
tion (Figure 2) is due to a failure of gadolinium contrast to penetrate
within the infarct core. Both CMR methods are T1-weighted but
contrast kinetics are not relevant for native T1 mapping since intra-
venous contrast is not administered. Accordingly, T1 mapping
avoids the theoretical risks and actual restrictions associated with
contrast-enhanced CMR. Furthermore, acquisition of the native
T1 map does not prolong the CMR scan, in contrast to late gadolin-
ium enhancement imaging for microvascular obstruction which is
typically imaged 10–15 min after dosing.19
Culprit artery coronary flow at the end of emergency PCI reflects
the efficacy of coronary reperfusion, and reduced coronary flow ini-
tially independently predicted native T1 relaxation time within in-
farct core as assessed by CMR 2 days later. Similar associations
also exist for microvascular obstruction,44,45 and in our study,
both infarct core native T1 and microvascular obstruction were in-
dependently associated with circulating biomarkers of acute system-
ic inflammation. The occurrence of an infarct core disclosed by
native T1 mapping, and the nature of the core (i.e. the native T1 va-
lue), was associated with the initial severity of MI (i.e. Killip heart fail-
ure class), systemic inflammation (i.e. leucocyte counts), and LV
remodelling and health outcomes in the longer term. We think
that the prognostic significance of native T1 values within the
hypo-intense core are a distinctive attribute compared with micro-
vascular obstruction since signal-intensity values within microvascu-
lar obstruction are not clinically meaningful beyond binary
categorization (i.e. present/absent).
Limitations
We performed a single centre natural-history study involving near-
consecutive STEMI admissions. The STEMI patients in our natural-
history study were recruited 24/7 therefore flow cytometry and
routine NT-proBNP testing in all participants was not pragmatically
possible.
T1 assessment is sensitive to motion artefacts and imperfect
breath holding, which and may reduce image quality. A shortened
version of this sequence (ShMOLLI) involving only nine heart beats
has been developed. This method shortens breath hold time and
may help to account for these limitations.42 Despite this, the MOLLI
method has high precision reproducibility. Our T1 measurements
are in good agreement with in vivo data published in the literature,
including previous measurements using the ShMOLLI sequence.42,43
The limited number of adverse events constrained the number of
variables that could be included in the multivariable models (e.g.
Tables 4 and 6); however, the associations between infarct core
native T1 and a range of surrogate and clinical outcomes including
adverse remodelling revealed by CMR, NT-proBNP, and the
primary health outcome (all-cause death/heart failure), supports
the adverse prognostic importance of infarct core native T1. Our
study does not permit inference on causality, and other interpreta-
tions of our data are possible and further studies are warranted.
Conclusions
We found that infarct core pathology revealed by native T1 maps
had similar prognostic value compared with microvascular obstruc-
tion revealed by late gadolinium enhancement CMR. Native T1
mapping is potentially widely applicable in clinical practice, not lim-
ited by renal disease, and so potentially could represent an alterna-
tive non-contrast CMR option for the assessment of infarct
pathology.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Optical coherence tomography-guided percutaneous coronary intervention
in pre-terminal chronic kidney diseasewith no radio-contrast administration
Keyvan Karimi Galougahi1,2, Adrian Zalewski1, Martin B. Leon1,3, Dimitri Karmpaliotis1,3, and Ziad A. Ali1,3*
1Division of Cardiology, Center for Interventional Vascular Therapy, New York Presbyterian Hospital and Columbia University, New York, NY, USA; 2Sydney Medical School
Foundation, University of Sydney, Australia; and 3Cardiovascular Research Foundation, New York, NY, USA
* Corresponding author. Tel: +1 212 3057060, Email: zaa2112@columbia.edu
A 67-year-old man with advanced chronic kidney
disease (CKD) (creatinine ¼ 4.5 mg/dL, eGFR ¼
13 mL/min/1.73 m2) not requiring haemodialysis
presented with progressive angina. Diagnostic
angiography with ultra-low radio-contrast volume
(12 mL, contrast volume/eGFR ratio ,1) re-
vealed significant stenosis in the left anterior
descending (LAD) artery (Panel A). The lesion
was haemodynamically significant (fractional
flow reserve: 0.77). Post-angiography, the renal
function remained stable. A staged percutaneous
coronary intervention (PCI) was performed
without utilizing radio-contrast medium. Previous
angiographic images were used to guide catheter
engagement and guidewire placement in the LAD
and diagonal arteries, thus creating a metallic sil-
houette of the artery (Panel B). Repeat physio-
logical assessment confirmed haemodynamic significance [FFR: 0.78, coronary flow reserve (CFR): 1.4]. Optical coherence
tomography (OCT) with angiographic co-registration (OptisI, St Jude Medical, MA) was performed using a mixture of saline and colloid
infusate to displace blood (Panels C and D). Proximal (Panel E) and distal (Panel G) reference diameters determined by measuring the
distance between respective external elastic laminae and minimal luminal area (Panel F) were used for selection of the pre-dilation
balloon and stent sizes. An automated angiographic co-registered OCT pullback was used to guide the PCI (Panels H and I, G: distal
reference ¼ white bar). Co-registered OCT was repeated to determine minimal stent area (Panels J and K) and to guide post-dilation.
Post-procedure FFR improved to 0.93 and CFR to 3.0. Post-PCI renal function remained stable. This case highlights the feasibility of radio-
contrast free OCT-angiographic co-registration guided PCI to prevent contrast-induced nephropathy and requirement for renal replace-
ment therapy in selected extremely high-risk patients with near end-stage CKD.
Conflict of interest: D.K. has served as a speaker or a member of the speaker’s bureau for Abbott Vascular, Boston Scientific and
Medtronic. Z.A.A. is a speaker for and holds grant support from St Jude Medical.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: journals.permissions@oup.com.
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